Hypertriglyceridemia: Impact and Treatment
Tài liệu tham khảo
Hahn, 1943, Abolishment of alimentary lipemia following injection of heparin, Science, 98, 19, 10.1126/science.98.2531.19
Havel, 1960, Idiopathic hyperlipidemia: metabolic studies in an affected family, J Clin Invest, 39, 1777, 10.1172/JCI104202
Sukonina, 2006, Angiopoietin-like protein 4 converts lipoprotein lipase to inactive monomers and modulates lipase activity in adipose tissue, Proc Natl Acad Sci U S A, 103, 17450, 10.1073/pnas.0604026103
LaRosa, 1970, A specific apoprotein activator for lipoprotein lipase, Biochem Biophys Res Commun, 41, 57, 10.1016/0006-291X(70)90468-7
Brown, 1972, Inhibition of lipoprotein lipase by an apoprotein of human very low density lipoprotein, Biochem Biophys Res Commun, 46, 375, 10.1016/S0006-291X(72)80149-9
Beigneux, 2007, Glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 plays a critical role in the lipolytic processing of chylomicrons, Cell Metab, 5, 279, 10.1016/j.cmet.2007.02.002
Kathiresan, 2008, Defining the spectrum of alleles that contribute to blood lipid concentrations in humans, Curr Opin Lipidol, 19, 122, 10.1097/MOL.0b013e3282f70296
Coburn, 2000, Defective uptake and utilization of long chain fatty acids in muscle and adipose tissues of CD36 knockout mice, J Biol Chem, 275, 32523, 10.1074/jbc.M003826200
Fukuchi, 1999, Enhanced myocardial glucose use in patients with a deficiency in long-chain fatty acid transport (CD36 deficiency), J Nucl Med, 40, 239
Goldberg, 1996, Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherogenesis, J Lipid Res, 37, 693, 10.1016/S0022-2275(20)37569-6
Brunzell, 1973, Evidence for a common, saturable, triglyceride removal mechanism for chylomicrons and very low density lipoproteins in man, J Clin Invest, 52, 1578, 10.1172/JCI107334
Hammarstedt, 2008, High circulating levels of RBP4 and mRNA levels of aP2, PGC-1alpha and UCP-2 predict improvement in insulin sensitivity following pioglitazone treatment of drug-naive type 2 diabetic subjects, J Intern Med, 263, 440, 10.1111/j.1365-2796.2007.01914.x
Savonen, 1999, Chylomicron metabolism in an animal model for hyperlipoproteinemia type I, J Lipid Res, 40, 1336, 10.1016/S0022-2275(20)33496-9
Chait, 1992, Chylomicronemia syndrome, Adv Intern Med, 37, 249
Ginsberg, 1996, Diabetic dyslipidemia: basic mechanisms underlying the common hypertriglyceridemia and low HDL cholesterol levels, Diabetes, 45, S27, 10.2337/diab.45.3.S27
Wilson, 1990, Phenotypic expression of heterozygous lipoprotein lipase deficiency in the extended pedigree of a proband homozygous for a missense mutation, J Clin Invest, 86, 735, 10.1172/JCI114770
Goldberg, 2001, Lipoprotein lipase: physiology, biochemistry, and molecular biology, Front Biosci, 6, D388, 10.2741/Goldberg
Krauss, 1974, Selective measurement of two lipase activities in postheparin plasma from normal subjects and patients with hyperlipoproteinemia, J Clin Invest, 54, 1107, 10.1172/JCI107855
Brunzell, 1983, Familial chylomicronemia due to a circulating inhibitor of lipoprotein lipase activity, J Lipid Res, 24, 12, 10.1016/S0022-2275(20)38019-6
Tolentino, 2002, Combination of gemfibrozil and orlistat for treatment of combined hyperlipidemia with predominant hypertriglyceridemia, Endocr Pract, 8, 208, 10.4158/EP.8.3.208
Rouis, 1997, Therapeutic response to medium-chain triglycerides and omega-3 fatty acids in a patient with the familial chylomicronemia syndrome, Arterioscler Thromb Vasc Biol, 17, 1400, 10.1161/01.ATV.17.7.1400
2002, Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report, Circulation, 106, 3143, 10.1161/circ.106.25.3143
Austin, 2000, Cardiovascular disease mortality in familial forms of hypertriglyceridemia: a 20-year prospective study, Circulation, 101, 2777, 10.1161/01.CIR.101.24.2777
Voyiaziakis, 1998, ApoA-I deficiency causes both hypertriglyceridemia and increased atherosclerosis in human apoB transgenic mice, J Lipid Res, 39, 313, 10.1016/S0022-2275(20)33893-1
Jacobson, 2007, Hypertriglyceridemia and cardiovascular risk reduction, Clin Ther, 29, 763, 10.1016/j.clinthera.2007.05.002
Nordestgaard, 2007, Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women, J Am Med Assoc, 298, 299, 10.1001/jama.298.3.299
Bansal, 2007, Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women, J Am Med Assoc, 298, 309, 10.1001/jama.298.3.309
Benlian, 1996, Premature atherosclerosis in patients with familial chylomicronemia caused by mutations in the lipoprotein lipase gene, N Engl J Med, 335, 848, 10.1056/NEJM199609193351203
Zhang, 2008, Spontaneous atherosclerosis in aged lipoprotein lipase deficient mice with severe hypertriglyceridemia on a normal chow diet, Circ Res, 102, 250, 10.1161/CIRCRESAHA.107.156554
Nordestgaard, 1988, Large lipoproteins are excluded from the arterial wall in diabetic cholesterol-fed rabbits, J Lipid Res, 29, 1491, 10.1016/S0022-2275(20)38428-5
Detrano, 2008, Coronary calcium as a predictor of coronary events in four racial or ethnic groups, N Engl J Med, 358, 1336, 10.1056/NEJMoa072100
Lieber, 2004, Alcoholic fatty liver: its pathogenesis and mechanism of progression to inflammation and fibrosis, Alcohol, 34, 9, 10.1016/j.alcohol.2004.07.008
Le, 2006, Metabolic effects of fructose, Curr Opin Clin Nutr Metab Care, 9, 469, 10.1097/01.mco.0000232910.61612.4d
Lee, 2003, Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors, Endocrinology, 144, 2201, 10.1210/en.2003-0288
Andersson, 1999, Developmental and pharmacological regulation of apolipoprotein C-II gene expression. Comparison with apo C-I and apo C-III gene regulation, Arterioscler Thromb Vasc Biol, 19, 115, 10.1161/01.ATV.19.1.115
Brown, 1987, Potential use of fenofibrate and other fibric acid derivatives in the clinic, Am J Med, 83, 85, 10.1016/0002-9343(87)90876-X
Gotto, 1998, Triglyceride as a risk factor for coronary artery disease, Am J Cardiol, 82, 22Q, 10.1016/S0002-9149(98)00770-X
Rubins, 1999, Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group, N Engl J Med, 341, 410, 10.1056/NEJM199908053410604
Robins, 2001, Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial, J Am Med Assoc, 285, 1585, 10.1001/jama.285.12.1585
Bellosta, 2004, Safety of statins: focus on clinical pharmacokinetics and drug interactions, Circulation, 109, III50
Keech, 2005, Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial, Lancet, 366, 1849, 10.1016/S0140-6736(05)67667-2
McKenney, 2007, Role of prescription omega-3 fatty acids in the treatment of hypertriglyceridemia, Pharmacotherapy, 27, 715, 10.1592/phco.27.5.715
Pan, 2004, Lipid peroxidation and oxidant stress regulate hepatic apolipoprotein B degradation and VLDL production, J Clin Invest, 113, 1277, 10.1172/JCI19197
Qi, 2002, Omega-3 triglycerides modify blood clearance and tissue targeting pathways of lipid emulsions, Biochemistry, 41, 3119, 10.1021/bi015770h
Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico, 1999, Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial, Lancet, 354, 447, 10.1016/S0140-6736(99)07072-5
Arad, 1992, Effects of lovastatin therapy on very-low-density lipoprotein triglyceride metabolism in subjects with combined hyperlipidemia: evidence for reduced assembly and secretion of triglyceride-rich lipoproteins, Meta, 41, 487, 10.1016/0026-0495(92)90206-P
Kusunoki, 2000, The lipoprotein lipase activator, NO-1886, suppresses fat accumulation and insulin resistance in rats fed a high-fat diet [in process citation], Diabetologia, 43, 875, 10.1007/s001250051464
Goldberg, 2005, A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia, Diabetes Care, 28, 1547, 10.2337/diacare.28.7.1547